STADA signs agreement to commercialize Rupafin® (rupatadine) in the MENA region
One documentmore
Stories from Bad Vilbel
STADA extends ViruProtect partnership with Enzymatica to cover Nordic region
One documentmoreSTADA extends ViruProtect partnership with Enzymatica to cover Nordic region
One documentmore
2Nico Reinhold new Global Head of Digital Communications at STADA
One documentmoreSTADA and PharmaMar sign agreement to commercialize Yondelis® (trabectedin) in the MENA region
One documentmoreEnyzmatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukraine and CIS countries
One documentmoreEuropean Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs
One documentmoreSTADA expands specialty footprint through acquisition of innovative therapy for treating advanced Parkinson's disease
One documentmoreSTADA's US partner Supernus submits NDA for apomorphine infusion pump
One documentmore-
Press release - Romaniszyn leads STADA Poland's growth strategy
One documentmore STADA continues to grow strongly during challenging times
One documentmorePress Release: Nidda Healthcare GmbH sets cash compensation for the transfer of the shares of the minority shareholders of STADA Arzneimittel AG at 98.51 EUR
One documentmoreKOPIE VON: Nidda Healthcare GmbH intends to conduct a squeeze-out of minority shareholders in STADA Arzneimittel AG under stock corporation law
One documentmoreNidda Healthcare GmbH intends to conduct a squeeze-out of minority shareholders in STADA Arzneimittel AG under stock corporation law
One documentmore-
Press release: Alvotech and STADA agree on strategic biosimilar partnership
One documentmore STADA Health Report 2019: Half of Europeans are ready for Dr Robot and treatments via webcam
more
1